Novo Nordisk’s Ozempic named in latest Medicare price negotiations
The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix’s busy year
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy
Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Analysis
View More
Themes
View MorePfizer believes in the metaverse: will healthcare thaw the technology’s winter?
The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
JP Morgan 2025: Incyte expects period of ‘defining catalysts’
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
FDA CDER director Patrizia Cavazzoni announces resignation
Artificial intelligence and atopic dermatitis: A new era for disease management?